Cancer clinical trials in the region Occitanie

415 currently recruiting clinical trials
Region Occitanie
Phase 3 Acute leukemia #NCT06852222 #2024-520154-38-00
Required histologic types
Acute myeloid leukemia (AML)
Required central nervous system lesions
None Treated / Controled
Required genetic anomalies
KMT2A NPM1
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
13 recruiting sites
Janssen
Phase 3 Acute leukemia #NCT05907057 #2022-501709-11
Required histologic types
Acute myeloid leukemia (AML)
Required genetic anomalies
IDH1/2
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive Chemotherapy
3 recruiting sites
Servier
Phase 3 Breast cancer #NCT06435429
Required HER2 statuses
HER2 Positive
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Antibody Drug Conjugates (ADC)
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
15 recruiting sites
Jazz Pharmaceuticals
Phase 3 Prostate cancer #NCT07213674 #2025-520555-89-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Hormone therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
13 recruiting sites
Amgen
Phase 3 Endometrial cancer #NCT06712472 #2023-503886-44-00
Required histologic sub types
Endometrioid adenocarcinoma Serous adenocarcinoma Clear cell carcinoma Dedifferentiated and undifferentiated endometrial ... Carcinosarcoma
Required FIGO stages
Stage I Stage II Stage III
Required disease stage
Localized Locally Advanced
Required genetic anomalies
TP53
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Surgery Chemotherapy Radiotherapy
Excluded genetic anomalies
MSI/dMMR POLE
14 recruiting sites
Gustave Roussy, Campus du cancer, Grand Paris
Phase 3 Prostate cancer #NCT06952803 #2024-513586-39-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Localized Biochemical recurrence
Required genetic anomalies
BRCA 1/2
Required previous treatments at localized stage
Radiotherapy Hormone therapy
Excluded previous treatments at localized stage
Immunotherapy Chemotherapy Targeted therapy
19 recruiting sites
AstraZeneca
Phase 3 Lymphoma #NCT06084936
Required histologic types
B cell lymphoma
Required histologic sub types
Mantel cell lymphoma
Required central nervous system lesions
None
Required number of previous lines of therapy
1 2 3 or more
Excluded previous treatments
Systemic Treatment-Naive Car-T Bispecific T-cell engager antibodies Allogeneic stem cell transplant
5 recruiting sites
Hoffmann-La Roche
Phase 3 Bladder / Urinary Tract / Urethral cancer #NCT06919965
Required histologic types
Non-invasive bladder cancer
Required histologic sub types
Urothelial carcinoma
Required disease stage
Localized
Required genetic anomalies
FGFR
Required number of previous lines of therapy for current stage of disease
None 1
Required previous treatments at localized stage
Immunotherapy
7 recruiting sites
Janssen
Phase 3 Lymphoma #NCT06742996 #2024-515593-27-00
Required histologic types
B cell lymphoma
Required histologic sub types
Mantel cell lymphoma
Required central nervous system lesions
None
Required number of previous lines of therapy
1 2 3 or more
Required previous treatments
Chemotherapy Monoclonal antibodies
Excluded previous treatments
Systemic Treatment-Naive
2 recruiting sites
BeOne Medecines
Phase 3 Breast cancer #NCT06195709 #2023-506282-66-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Targeted therapy Hormone therapy
Excluded previous treatments at advanced or metastatic stage
Chemotherapy Car-T Bispecific T-cell engager antibodies Antibody Drug Conjugates (ADC)
10 recruiting sites
Institut Curie